Uncategorized
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
The FDA has been trying to mend fences with rare disease drug developers and patient groups since the departure of former Commissioner Marty Makary three months ago. But advisory committee meetings last week for Replimune and Capricor Therapeutics only created more confusion and frustration.